Solid state forms of a selective potassium channel modulator

Abstract

The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

1 . A solid amorphous form of Compound A,
 wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.   
     
     
         2 - 7 . (canceled) 
     
     
         8 . A pharmaceutical composition comprising the solid amorphous form of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         9 - 12 . (canceled) 
     
     
         13 . A pharmaceutical composition comprising the solid amorphous form of  claim 1  and a pharmaceutically acceptable excipient, carrier, or diluent. 
     
     
         14 . A method of treating a seizure disorder in a human, wherein the method comprises administering a therapeutically effective amount of a solid amorphous form of Compound A to the human in need thereof,
 wherein Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.   
     
     
         15 - 19 . (canceled) 
     
     
         20 . A method of preparing the solid amorphous form of  claim 1 , comprising heating a crystalline form of Compound A, whereby said heating results in formation of the solid amorphous form of Compound A. 
     
     
         21 . A method of preparing the pharmaceutical composition of  claim 8 , the method comprising combining the solid amorphous form of Compound A with the pharmaceutical excipient thereby forming the pharmaceutical composition. 
     
     
         22 . The method of  claim 14 , wherein the solid amorphous form is administered to the human from between 30 minutes before to 2 hours after eating a meal. 
     
     
         23 . The method of  claim 22 , wherein the solid amorphous form is administered during a meal or within 15 minutes after eating a meal. 
     
     
         24 . The method of  claim 20 , wherein said heating comprises heating the crystalline form of Compound A to at least 170 C. 
     
     
         25 . The method of  claim 24 , wherein said heating comprises heating the crystalline form of Compound A to at least 180 C. 
     
     
         26 . The method of  claim 25 , wherein said heating comprises heating the crystalline form of Compound A to at least 190 C. 
     
     
         27 . The method of  claim 26 , further comprising cooling the Compound A to 25 C. 
     
     
         28 . The method of  claim 27 , further comprising cooling the Compound A to 25 C. 
     
     
         29 . The method of  claim 28 , further comprising cooling the Compound A to 25 C.